Orilissa vs. Lupron vs. Myfembree: GnRH Comparison

It is 2 a.m., the heating pad is on its third reheat, and your provider just floated a drug name you have never heard of as the next step. Now you are searching at midnight, trying to figure out the real differences between three medications that all sound the same in the patient brochure.

How Do Orilissa, Lupron, and Myfembree Compare at a Glance?

All three drugs are FDA-approved for endometriosis pain, and all three lower estrogen to control the disease. They differ across seven things you actually feel: the kind of drug it is, how you take it, how many dose options you have, how long you can stay on it, whether bone-protecting hormones are built in, how much bone density it costs you, and how much it costs in dollars. According to a 2025 JAMA review, GnRH-based therapies are classified as second-line treatments for endometriosis — meaning they’re tried after birth control pills and progestins, not before them.

The “newer is better” framing flattens a real clinical trade-off. Each drug fits a different person. Whether you have pain during sex on top of period pain, whether you started with a low bone-density baseline, whether you can take a pill every day without missing doses, and whether you have a history of depression or anxiety all change which one is the right starting point. None of these factors fit on a marketing one-pager.

How Does Each GnRH Drug Work?

All three drugs lower estrogen to shrink endometriosis lesions, but they reach that goal through different mechanisms and at different speeds. The antagonists (Orilissa, Myfembree) block GnRH receptors in the brain within hours. The agonist (Lupron) first floods the receptors, causing a temporary hormonal surge, and only suppresses estrogen after about two weeks. Understanding which class your drug belongs to predicts how the first month will feel.

Orilissa (elagolix) — GnRH antagonist

Orilissa blocks GnRH receptors directly, lowering estrogen within 24 hours of the first dose. According to a 2021 Lancet review, the once-daily 150 mg regimen brings your average estrogen level down to about 42 pg/mL — enough to reduce pain while keeping a small amount of estrogen circulating. The 200 mg twice-daily regimen drops it further, to about 12 pg/mL, which is more effective for pain but produces more menopause-like symptoms. The ability to step up or down between two doses based on your symptoms is unique to Orilissa.

Lupron (leuprolide) — GnRH agonist

Lupron works in the opposite direction at first. According to the FDA label, the first injection causes a temporary surge in your cycle hormones — the “flare effect” — that can actually worsen pain for about two weeks before estrogen finally drops. After that, Lupron suppresses estrogen to a level similar to menopause. ACOG guidance suggests starting Lupron about one week before your period to minimize the flare; talk to your provider about timing.

Myfembree (relugolix combination therapy) — GnRH antagonist with built-in add-back

Myfembree combines a GnRH antagonist (relugolix) with a low dose of estrogen and a progestin in a single daily pill. According to the SPIRIT 1 and 2 trials published in The Lancet in 2022, the combination keeps your estrogen in a therapeutic window — high enough to protect your bones and reduce hot flashes, low enough to control endometriosis. The clinical principle behind add-back was established years before Myfembree existed: partial suppression of estrogen in roughly the 30–60 pg/mL range is the best balance of pain control, fewer side effects, and bone safety. Myfembree was engineered to live in that window.

Which of These GnRH Drugs Is Most Effective for Endometriosis Pain?

In large clinical trials, roughly 75% of patients on high-dose Orilissa or Myfembree had clinically meaningful improvement in period pain at six months, compared to 19–30% on placebo. A 2026 systematic review and meta-analysis of more than 2,000 patients across five phase 3 trials found that oral GnRH antagonists significantly reduced both period pain and everyday pelvic pain, with a number needed to treat of just 2 for period pain relief. According to a 2021 Lancet review, approximately 85% of women on Lupron experience pain relief, although direct head-to-head trials between Lupron and the newer oral options are limited.

The picture for low-dose Orilissa is more modest. In the ELARIS trials, low-dose elagolix produced a meaningful response in period pain in roughly 43–46% of patients, and it did not significantly improve pain during sex. The high dose did improve pain during sex — which is why patients with deep, penetrative pain are often started on the high dose despite its tighter 6-month time limit.

“The honest framing I give patients: even on the best of these drugs, about one in five women will get no meaningful pain reduction at all. That isn’t a failure of you — it’s a sign that lesion suppression isn’t the only driver of your pain.”

— Heather Yoshimura, NP, MSN

According to a 2025 JAMA review, even with hormonal therapy, 11–19% of women experience no pain reduction at all, and a much larger group still has some leftover pain at the end of the treatment window. There is no GnRH drug that is a guaranteed fix — and that is not a failure of any single medication. It is a signal that endometriosis pain has multiple drivers beyond lesion suppression. Pelvic floor tension, a sensitized nervous system, and gut and hormonal contributors can all keep pain alive even when estrogen is fully suppressed. If a GnRH drug isn’t working, that is information — not a verdict on you.

What Are the Side Effects of Orilissa, Lupron, and Myfembree?

Hot flashes are the most common side effect across all three drugs, but the rates vary dramatically. In the elagolix trials, low-dose Orilissa caused hot flashes in roughly a quarter to nearly half of patients; high-dose Orilissa, in nearly half to more than three-quarters. In the SPIRIT trials, Myfembree caused hot flashes in only about 10–14% of patients. According to the Lupron FDA label, hot flashes are the most commonly reported side effect, occurring in more than 10% of patients. The difference is mostly about whether bone-protecting hormones are built in.

Hot flashes and menopause-like symptoms

Hot flashes, night sweats, and vaginal dryness all reflect how deeply each drug lowers your estrogen. Low-dose Orilissa keeps estrogen around 42 pg/mL, which produces the mildest symptoms of the bunch. Myfembree’s built-in add-back keeps estrogen in a similar range. High-dose Orilissa drops estrogen to about 12 pg/mL, and Lupron suppresses it even further — which is why both produce more symptoms. If hot flashes are unbearable, the fix isn’t always switching drugs. Sometimes it’s adding separate hormonal add-back therapy, or stepping down to a lower dose.

Bone density risk

All three drugs cause some bone loss; the question is how much. High-dose Orilissa taken on its own causes about 2.4% bone loss in the lower spine at six months. Myfembree causes less than 1% loss at six months — below the threshold for clinical significance. Lupron with add-back loses about 1.3% of bone density at six months. Lupron without add-back loses substantially more, which is the reason the FDA limits Lupron-alone treatment to 6 months in the first place.

Mood effects

Mood changes are real and underdiscussed. The Orilissa FDA label carries a specific warning about new or worsening depression and thoughts of self-harm. In the ELARIS trials, depressed mood occurred in about 3% of patients on the low dose and roughly 6% on the high dose. The Lupron FDA label carries a similar warning: clinical depression may show up or get worse, particularly in patients with a history of it. In the SPIRIT trials, Myfembree was associated with mood-related side effects in about 9% of patients. If you have a history of depression, anxiety, PMDD (premenstrual dysphoric disorder), or trauma, this is a non-optional conversation with your provider before starting. The interaction between hormonal suppression and a sensitized nervous system is real — see endometriosis, depression, and anxiety for how the brain and body connect.

How Long Can You Take Orilissa, Lupron, or Myfembree?

Duration limits are one of the most practical differences between the three drugs. Low-dose Orilissa (150 mg daily) is approved for up to 24 months. High-dose Orilissa (200 mg twice daily) is capped at 6 months due to bone loss. Lupron alone is approved for 6 months; with add-back therapy, it can be extended to 12 months. Myfembree is approved for up to 24 months in the U.S. and has been approved without a strict time limit in some European countries.

One outdated claim that still circulates: “GnRH drugs are limited to 6 months.” That has not been true for low-dose Orilissa or Myfembree for several years. The 24-month window matters enormously for a chronic disease that needs ongoing management. It’s the difference between a short bridging therapy and a real treatment option — and it’s one of the reasons the conversation around GnRH drugs has shifted since 2020.

How Much Do Orilissa, Lupron, and Myfembree Cost?

All three drugs are expensive at list price. According to a 2019 Human Reproduction analysis, Orilissa launched at about $845 per month — roughly $10,000 per year — making it many times more expensive than first-line birth control or progestin options. Lupron Depot runs about $1,000 to $1,700 per injection depending on which version you get, plus the cost of the office visit. Myfembree lists at about $1,000 per month.

With insurance, real out-of-pocket costs vary wildly. All three drug companies run copay assistance programs that can reduce monthly costs to $0–$30 for patients on commercial insurance plans. Prior authorization is almost always required. Some plans prefer one drug over another — generic versions of leuprolide exist, which can give Lupron a small advantage with some insurers, though brand Lupron Depot is still the most commonly prescribed form. Have your prescriber’s office check your specific plan before you assume a drug will be covered. Surprise denials are the single most common reason patients delay starting.

Who Is Each GnRH Drug Best Suited For?

There is no single best GnRH drug for endometriosis — the right starting point depends on your specific situation. According to a 2021 Lancet review, about a third of women don’t respond to first-line hormonal therapy (birth control pills or progestins) because of progesterone resistance or intolerable side effects, and that’s exactly the population GnRH drugs were built for. That number climbs even higher in women with deep endometriosis lesions.

• Low-dose Orilissa may suit patients with moderate period pain who want a longer treatment window (up to 24 months) and prefer not to take separate add-back hormones.
• High-dose Orilissa may be appropriate for patients with severe pain including pain during sex, who need maximum suppression for a shorter period (up to 6 months) — often as a bridge to surgery or a longer-term plan.
• Lupron may be preferred when remembering a daily pill is hard (a single in-office injection covers one to three months), as a recurrence-prevention strategy after surgery, or when an established track record matters. It’s also the drug most insurers cover most reliably.
• Myfembree may be the best fit for patients who want a single daily pill with built-in bone protection — especially those planning to use the medication for longer than 6 months or who already have lower-than-average bone density.

The question is not just “which drug is most effective.” The better question is, “which drug is most effective for your drivers of pain?” If progesterone resistance is the reason your birth control or progestin stopped working, moving to a GnRH-based drug makes biological sense. If your pain is driven mostly by pain during sex, the high-dose Orilissa or Myfembree data matters more than the period-pain data. If you have a history of depression, the mood data matters more than the bone-density data. The drug is one variable. Your body is the other.

Important safety notes. Myfembree carries the FDA’s strongest warning for increased blood-clot risk because it contains estrogen. It should not be taken by patients over 35 who smoke, by patients with uncontrolled high blood pressure, or by patients with a history of blood clots, stroke, or migraine with aura. All three drugs are off-limits if you have osteoporosis, significant liver disease, or are currently pregnant. None of them reliably prevent pregnancy — you need separate non-hormonal birth control while on any of them.

When Should You Consider Switching GnRH Medications?

Switching is reasonable if pain has not improved after three months of consistent use, if side effects are intolerable, or if you have reached the maximum approved duration. According to a 2025 JAMA review, 25–34% of women with endometriosis experience returning pelvic pain within 12 months of stopping hormonal therapy — so having a plan for what comes next is just as important as the drug you start on.

If one GnRH drug doesn’t work, another might. They are not interchangeable in how individual patients respond. Switching from Lupron to an oral pill like Orilissa or Myfembree is common when patients want to avoid injections, experience strong mood effects from the deeper estrogen suppression, or hit the 6-month duration limit on Lupron alone. Switching from high-dose Orilissa to Myfembree is common when patients want bone protection without the hassle of adding separate add-back hormones.

What Should You Ask Your Provider Before Starting?

Before starting any GnRH-based medication, there are six questions every patient should ask. These aren’t about second-guessing your provider — they’re about making sure the decision is fully informed before you start a medication that affects bones, mood, and contraception.

• Has my bone density been checked, and is it safe for me to take this drug? A baseline bone density scan (DEXA) is reasonable if you have any risk factors for low bone density, are planning longer-term use, or are starting a drug without bone-protecting add-back hormones.
• How long do you recommend I stay on this medication, and what’s the plan when I stop? Even the 24-month window goes by quickly. Plan the exit before you start.
• Do I need separate add-back hormones, or are they built into the pill? This one question changes the entire side-effect profile.
• Will my insurance cover this, and is prior authorization needed? Have the office check your specific plan before the prescription is written.
• What should I use for birth control? None of these drugs reliably prevent pregnancy, and lowering your estrogen is not the same as becoming infertile.
• Should I be concerned about mood changes given my mental health history? If you have a history of depression, anxiety, PMDD, or trauma, this matters more than the bone-density question.

When to Seek Care

Contact your provider promptly if you experience any of the following while on Orilissa, Lupron, or Myfembree:

• Pelvic pain rated 7 out of 10 or higher that is not improving with your current treatment
• Fever above 100.4°F (38°C)
• Heavy vaginal bleeding (soaking more than one pad per hour for two or more hours)
• New or worsening depression, anxiety, or any thoughts of self-harm
• Yellowing of the skin or eyes, dark urine, or right upper abdominal pain (potential liver signal)
• Sudden leg swelling, chest pain, or shortness of breath — particularly on Myfembree (blood clot risk)
• Severe headache, vision changes, or one-sided weakness — particularly on Myfembree (stroke signal)

Key Takeaways

• Orilissa, Lupron, and Myfembree are all FDA-approved second-line treatments for endometriosis pain — typically tried after birth control pills and progestins.
• Roughly 75% of patients respond to high-dose Orilissa or Myfembree for period pain, and according to a 2021 Lancet review, about 85% respond to Lupron.
• Low-dose Orilissa and Myfembree can be used for up to 24 months; high-dose Orilissa is limited to 6 months; Lupron with add-back is limited to 12 months.
• Bone loss at 6 months is less than 1% with Myfembree, about 2.4% with high-dose Orilissa taken on its own, and about 1.3% with Lupron plus add-back hormones.
• Hot flash rates range from about 10–14% on Myfembree to 42–77% on high-dose Orilissa — driven mostly by whether bone-protecting add-back hormones are built in.
• List prices run roughly $850–$1,700 per month; manufacturer copay programs can bring out-of-pocket cost to $0–$30 for patients with commercial insurance.
• None of the three reliably prevent pregnancy — you need separate non-hormonal birth control.
• According to a 2025 JAMA review, 11–19% of patients on hormonal therapy get no pain reduction at all, and 25–34% experience returning pain within 12 months of stopping — so the next-step plan matters as much as the drug.

Frequently Asked Questions

What is the difference between Orilissa, Lupron, and Myfembree?

All three lower estrogen to control endometriosis pain, but they take very different paths. Orilissa (elagolix) and Myfembree (relugolix) are oral GnRH antagonists that block hormone signaling within hours. Lupron (leuprolide) is an injectable GnRH agonist that first triggers a temporary hormone surge before deeply suppressing estrogen. Myfembree is the only one with built-in add-back hormones to protect bones. Orilissa is the only one with two dose options. Lupron is the only injection.

Which GnRH drug is best for endometriosis?

There’s no single best drug. Roughly 75% of patients respond to high-dose Orilissa or Myfembree for period pain, and according to a 2021 Lancet review, about 85% respond to Lupron. The right choice depends on your symptoms, your bone density baseline, whether you can take a pill daily versus prefer an injection, your tolerance for hot flashes and mood changes, and your insurance coverage. Switching between medications is common when one doesn’t work — they’re not interchangeable in how individual patients respond.

Do Orilissa, Lupron, and Myfembree cause bone loss?

Yes — all three cause some bone loss, but the degree varies dramatically. Myfembree causes less than 1% bone density loss in the lower spine at six months. High-dose Orilissa taken on its own causes about 2.4% loss. Lupron with add-back hormones causes about 1.3% loss at six months; without add-back, the loss is substantially larger, which is part of why Lupron taken alone is limited to 6 months. Myfembree’s built-in estrogen is the main reason its bone loss is the lowest of the three.

How long can I take Orilissa, Lupron, or Myfembree?

Duration limits differ. Low-dose Orilissa (150 mg daily) is FDA-approved for up to 24 months. High-dose Orilissa (200 mg twice daily) is limited to 6 months because of bone loss risk. Lupron alone is limited to 6 months; with add-back hormones, it can be extended to 12 months. Myfembree is approved for up to 24 months in the U.S. Many older articles still claim “GnRH drugs are limited to 6 months” — that’s outdated for both low-dose Orilissa and Myfembree.

What is the cost difference between Orilissa, Lupron, and Myfembree?

All three are expensive at list price. According to a 2019 Human Reproduction analysis, Orilissa was priced at about $845 per month (roughly $10,000 per year) at launch. Lupron Depot runs about $1,000 to $1,700 per injection depending on which version, plus the office visit fee. Myfembree lists at about $1,000 per month. With insurance, copays vary widely, and all three drug companies offer copay assistance programs that can bring out-of-pocket cost to $0–$30 per month for patients on commercial insurance. Prior authorization is almost always required.

The content on this page is for educational purposes only and is not medical advice. Always consult your healthcare provider for individualized guidance. Read our editorial policy.